<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113758</url>
  </required_header>
  <id_info>
    <org_study_id>ABZ-ECO-2018-01</org_study_id>
    <nct_id>NCT05113758</nct_id>
  </id_info>
  <brief_title>Sarcopenia Measured by Ultrasound in Hospitalized Older Adults</brief_title>
  <acronym>ECOSARC</acronym>
  <official_title>&quot;SARCOPENIA MEASURED BY ULTRASOUND IN HOSPITALIZED OLDER ADULTS&quot; (ECOSARC Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pedro Abizanda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Getafe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infanta Sofia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Infanta Leonor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Virgen del Valle de Toledo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Complejo Hospitalario Universitario de Albacete</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational prospective study in older adults admitted to an Acute Geriatric Unit, in which&#xD;
      sarcopenia will be evaluated by ultrasound in the anterior rectus femoris muscle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to estimate, by means of portable ultrasound, parameters&#xD;
      of muscle quantity and quality (anterior rectus femoris muscle area, width and echostructure&#xD;
      ) in older adults hospitalized in Acute Geriatric Units for medical reasons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of sarcopenia on admission</measure>
    <time_frame>72 hours</time_frame>
    <description>Prevalence of sarcopenia on admission. A prevalent case of sarcopenia will be considered if a patient fulfills the EWGSOP2 at admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of sarcopenia between admission and discharge</measure>
    <time_frame>15 days</time_frame>
    <description>An incident case of sarcopenia will be considered if a patient not fulfilling EWGSOP2 diagnostic criteria on admission, will meet diagnostic criteria at discharge of sarcopenia at discharge (diagnosis will be considered as a dichotomous variable -yes/no-).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle mass (the anterior rectus femoris muscle)</measure>
    <time_frame>15 days</time_frame>
    <description>The evolution of muscle mass between admission and discharge will be assessed by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal nutritional assessment (MNA-SF) score</measure>
    <time_frame>72 hours</time_frame>
    <description>The mini-nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in older adults. It takes into account the patient's loss of appetite, weight loss, motor skills, recent health status, neuropsychological disorders. The maximum score of the MNA-SF is 14:&#xD;
Greater than or equal to 11: normal nutritional status. Between 8 and 11: risk of malnutrition. Less than 8: malnutrition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand grip strength</measure>
    <time_frame>15 days</time_frame>
    <description>Using a hand-held dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-meter walking speed test</measure>
    <time_frame>15 days</time_frame>
    <description>The evolution of the value of the 4-meter walking speed test between admission and discharge will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADL (Activities of Daily Living) questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>the ADL questionnaire will also be performed on admission, at discharge, and at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPPB score (SHORT PHYSICAL PERFORMANCE BATTERY score)</measure>
    <time_frame>15 days</time_frame>
    <description>Short Physical Performance Battery (SPPB): score range 0-12, higher score means a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 months</time_frame>
    <description>Mortality will be measured with vital status at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay, days</measure>
    <time_frame>15 days</time_frame>
    <description>Day of admission to day of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission(s) after index hospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>Readmission(s) after index hospitalization, Dichotomous outcome (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency department (ED) visit(s)</measure>
    <time_frame>3 months</time_frame>
    <description>ED visit(s) after index hospitalization, Dichotomous outcome (yes/no)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">161</enrollment>
  <condition>Sarcopenia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>muscle ultrasound</intervention_name>
    <description>All participants will undergo a muscle ultrasound on admission and at discharge</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 69 years of age admitted to Acute Geriatric Units.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 69 years of age.&#xD;
&#xD;
          -  Hospitalization for a medical cause in Acute Geriatric Units.&#xD;
&#xD;
          -  Holden's Functional Ambulation Classification Scale at level 1 or higher.&#xD;
&#xD;
          -  Informed consent signed by the patient or legal representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminal condition or life expectancy of less than 6 months.&#xD;
&#xD;
          -  Impossibility or refusal to undergo muscle ultrasound.&#xD;
&#xD;
          -  Refusal for follow-up&#xD;
&#xD;
          -  Severe dementia stage Global Deteriorating Scale: 7&#xD;
&#xD;
          -  Impossibility in the opinion of the investigators to complete the necessary data for&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>69 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Abizanda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario de Albacete (SESCAM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Abizanda, MD, PhD</last_name>
    <phone>+34967597651</phone>
    <email>pabizanda@sescam.jccm.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Abizanda Soler, MD,PhD</last_name>
      <phone>+34967597684</phone>
      <email>pabizanda@sescam.jccm.es</email>
    </contact>
    <contact_backup>
      <last_name>Almudena Avendaño Céspedes, RN, PhD</last_name>
      <phone>+34967597684</phone>
      <email>aavendanoc@sescam.jccm.es</email>
    </contact_backup>
    <investigator>
      <last_name>Pedro Abizanda Soler, Head Geriatrics Department</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Complejo Hospitalario Universitario de Albacete</investigator_affiliation>
    <investigator_full_name>Pedro Abizanda</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sarcopenia</keyword>
  <keyword>ultrasound</keyword>
  <keyword>aged</keyword>
  <keyword>hospitalized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

